Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial Investigating Epcoritamab in Patients With Previously Treated Waldenstrom Macroglobulinemia (WM)

NCT06510491 is registered in ClinicalTrials.gov with Gottfried von Keudell, MD PhD as lead sponsor.

NCT NCT06510491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06510491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial Investigating Epcoritamab in Patients With Previously Treated Waldenstrom Macroglobulinemia (WM)
Lead sponsor
Gottfried von Keudell, MD PhD
Phase
Phase 2
Overall status
Recruiting
Start date
December 6, 2024
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoproliferative disorder, waldenstrom macroglobulinemia